Scleroderma, also called systemic sclerosis when it affects internal organs, is a rare autoimmune connective-tissue disease characterized by skin thickening, vascular dysfunction, and progressive fibrosis. Published estimates suggest on the order of tens of thousands of Americans live with the disease – roughly 75,000 to 100,000 by commonly cited figures, though exact counts vary by study – with women affected several times more often than men. Its reputation as one of the most challenging rheumatic diseases comes from its variable course: some people live for decades with stable skin disease, while others develop serious lung, heart, or kidney complications within a few years of onset. This guide is general education and is not a substitute for care from a qualified clinician; diagnosis and every treatment decision belong with your own doctor.
The Two Major Categories
Localized scleroderma affects the skin and underlying tissues without significant internal-organ involvement. Morphea (patches of thickened skin) and linear scleroderma (bands of skin tightening, sometimes affecting the muscle and bone beneath) are the main subtypes. As MedlinePlus notes, these forms often spare the hands and face, develop slowly, are more common in children, and rarely progress to systemic disease.
Systemic sclerosis affects the skin plus internal organs and is itself divided into limited cutaneous (lcSSc, historically described by the older CREST label) and diffuse cutaneous (dcSSc) forms. Limited disease shows skin thickening mainly on the hands, forearms, face, and feet, tends to progress slowly, and carries higher rates of pulmonary hypertension over time. Diffuse disease involves the trunk and upper arms and thighs, progresses faster, and carries a higher early risk of interstitial lung disease and renal crisis. Knowing which category you have shapes what your care team screens for and how closely.
Raynaud’s: Often the First Sign
Raynaud’s phenomenon – fingers turning white, then blue, then red in response to cold or stress – affects the large majority of scleroderma patients and often precedes other symptoms by years. Raynaud’s on its own is common and usually benign (primary Raynaud’s). But Raynaud’s accompanied by abnormal nailfold capillaries, specific autoantibodies, or skin changes points toward scleroderma or another connective-tissue disease and warrants evaluation. Our Raynaud’s phenomenon guide covers the difference in more depth.
Severe Raynaud’s in scleroderma can cause painful digital ulcers, tissue loss, and, rarely, gangrene. A range of medicines – calcium channel blockers first-line, with other vasodilators added for severe or refractory disease – are used, but which drug and what dose are decisions for your prescriber and are individualized. Practical self-care that genuinely helps includes protecting yourself from cold, not smoking (smoking narrows blood vessels), and avoiding drugs that cause vasoconstriction unless your doctor advises otherwise.
Skin Changes
Skin thickening typically begins in the fingers (sclerodactyly) and may progress to the hands, forearms, face, and beyond. Early disease can include puffy hands and, on exam, tendon friction rubs. As fibrosis advances, skin becomes tight, shiny, and sometimes darker or lighter than usual, with visible small dilated blood vessels (telangiectasias) on the face and hands.
Calcinosis – calcium deposits in the skin – affects a meaningful minority of patients and can ulcerate painfully. The old CREST acronym (Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, Telangiectasias) once described limited cutaneous disease but is no longer used in formal classification; clinicians now classify systemic sclerosis by validated criteria instead.
Internal Organ Involvement
Esophageal dysmotility is very common in systemic sclerosis, producing reflux, difficulty swallowing, and, over time, an increased risk of Barrett’s esophagus. Acid-suppressing medicines are often used long term under a clinician’s direction. Other GI problems – gastric antral vascular ectasia (“watermelon stomach”), small-bowel bacterial overgrowth, and constipation from colonic dysmotility – can complicate the picture and are managed individually.
Interstitial lung disease (ILD) is a leading cause of disease-specific death in scleroderma. It affects a substantial share of systemic sclerosis patients, and certain autoantibodies (such as anti-Scl-70/topoisomerase) mark elevated risk. Pulmonary function tests that track FVC and DLCO, together with high-resolution CT, guide diagnosis and monitoring. Our interstitial lung disease guide explains the testing in more detail.
Pulmonary arterial hypertension develops in a smaller share of patients over years, more often in the limited subtype. Because it can be silent until advanced, regular screening (typically with echocardiography and blood testing) is standard. Several drug classes can relax constricted lung blood vessels, but combinations and dosing are specialist-directed.
Scleroderma renal crisis – sudden severe high blood pressure with acute kidney injury – is a medical emergency. It occurs mainly in diffuse cutaneous disease, especially in the first few years and with higher-dose corticosteroid use. The introduction of ACE inhibitors transformed this once near-fatal complication into one that is often survivable when caught and treated promptly – which is exactly why the warning signs below must not be ignored.
If you have scleroderma and develop a sudden severe headache, very high blood pressure, blurred vision, sharply reduced or dark urine, severe shortness of breath, or confusion, this may be scleroderma renal crisis – a life-threatening emergency. Call 911 or go to the nearest emergency room immediately. Outcomes depend on rapid, prescriber-directed treatment (ACE inhibitors are the cornerstone). Do not wait to see whether it passes, and do not try to manage it at home.
Diagnosis
Diagnosis rests on the history and physical exam, blood tests, scleroderma-associated autoantibodies, and imaging of the heart and lungs, as the American College of Rheumatology describes. Validated classification criteria assign weight to features such as skin thickening of the fingers, puffy fingers, fingertip lesions, telangiectasias, abnormal nailfold capillaries, lung involvement, Raynaud’s, and specific autoantibodies; skin thickening extending up the fingers past the knuckles can be sufficient on its own.
Autoantibody testing helps predict the pattern of disease: anti-centromere antibodies are associated with limited disease and pulmonary-hypertension risk; anti-Scl-70 (topoisomerase I) with diffuse disease and ILD risk; and anti-RNA polymerase III with diffuse disease and renal-crisis risk. Other antibodies carry their own associations. Interpreting these results is a clinician’s job – the same antibody can mean different things in different people.
Modern Treatment Options
Treatment is organ-targeted, because no single therapy controls every manifestation – and, importantly, there is no cure. For early diffuse skin disease and for ILD, immunosuppressants such as mycophenolate are commonly used, and the ACR notes mycophenolate is used for scarring or inflammation of the lungs. For progressive ILD, antifibrotic therapy (nintedanib) and other agents such as rituximab or tocilizumab may be considered in appropriate patients. For pulmonary hypertension, targeted vasodilator drugs – sometimes in combination – can improve outcomes. For renal crisis, ACE inhibitors are the cornerstone and are typically continued even if kidney numbers worsen in the short term.
Autologous hematopoietic stem cell transplant has produced durable benefit in carefully selected patients with severe, rapidly progressive diffuse disease, but it carries real early risk and is offered only at specialized centers. This guide deliberately gives no doses, taper schedules, or “how much to take” – all of that is set and adjusted only by your prescribing clinician. Copying a regimen from the internet is dangerous with these powerful medicines: too little can let organ damage progress, and too much carries its own serious harms. If a medication feels wrong, call your prescriber rather than adjusting it yourself, and never stop an immunosuppressant abruptly on your own.
When to seek emergency care: Call 911 or go to the nearest emergency room for sudden severe shortness of breath, blue lips or fingers, a sudden severe headache with very high blood pressure (possible renal crisis), severe chest pain, sudden severe abdominal pain, signs of digital gangrene (black, painful fingertips), or signs of serious infection while on immunosuppressants (high fever, shaking chills, feeling very unwell). When you are unsure whether a symptom is dangerous, treat it as urgent and get seen.
Living With Scleroderma
Daily management emphasizes prevention and consistency. Cold protection – gloves, hand warmers, layered clothing – reduces Raynaud’s attacks. Regular moisturizing and gentle skin care help with dryness and tightness. Range-of-motion exercises help preserve hand and finger function as fibrosis progresses, and physical or occupational therapy can help.
Reflux management often includes raising the head of the bed, not eating in the few hours before lying down, weight management, small frequent meals, and consistent use of prescribed acid-suppressing medicine. Dental care matters, because a narrowing mouth opening and overlap dryness (Sjögren’s features are common) raise the risk of cavities.
Mental health support is important too. Body-image changes, fatigue, and the uncertainty of the disease all weigh on patients. Connecting with the Scleroderma Foundation and patient communities provides peer support that complements medical care. Because scleroderma is a lifelong condition needing specialist oversight, it also helps to plan for the cost of ongoing care and medicines – see our healthcare costs guide. Our medical conditions overview and Sjögren’s syndrome guide cover related autoimmune conditions.
When to See a Doctor
New Raynaud’s phenomenon – especially in an older adult, or with finger ulcerations, abnormal nailfold capillaries, or a positive ANA – warrants rheumatology evaluation. New skin tightening, puffy fingers, or unexplained shortness of breath in someone with known autoimmunity also justifies prompt evaluation. Getting to a diagnosis early, rather than living with unexplained symptoms for years, is one of the most valuable steps you can take.
Once scleroderma is established, regular screening is the point: periodic checks for ILD (pulmonary function tests), pulmonary hypertension (echocardiogram and blood tests), and kidney involvement (blood pressure, kidney function, urinalysis). Care is best coordinated by a rheumatologist, with pulmonology, cardiology, and gastroenterology involved as needed.
Frequently Asked Questions
Is scleroderma fatal?
It can be in severe systemic sclerosis with major organ involvement, particularly lung and kidney complications. Localized scleroderma is generally not life-shortening. Modern treatment of ILD, pulmonary hypertension, and renal crisis has improved survival, but systemic sclerosis remains one of the more serious connective-tissue diseases, which is why monitoring matters.
What is the life expectancy with scleroderma?
It varies widely. Many people with limited cutaneous disease have a near-normal life expectancy, while diffuse disease with significant organ involvement carries a higher risk. Outcomes have improved considerably with current therapies and close monitoring. Your own outlook depends on the specific pattern of your disease – discuss it with your rheumatologist.
Is scleroderma hereditary?
Genetic susceptibility plays a role, but the disease is not directly inherited. First-degree relatives have only a small increase in risk. Environmental exposures, including silica and certain solvents, have been implicated in some cases.
Can scleroderma be cured?
No – there is currently no cure. However, treatment has expanded significantly: managing organ involvement, antifibrotic therapy for ILD, pulmonary-hypertension drugs, ACE inhibitors for renal crisis, and stem cell transplant for severe disease can meaningfully change the course. Patients have more options than ever, and outcomes continue to improve.
What is scleroderma renal crisis, and why is it urgent?
It is a sudden onset of severe high blood pressure with acute kidney injury, most often in diffuse disease and early in its course. It is a medical emergency because outcomes depend on rapid treatment (ACE inhibitors are central). Sudden severe headache, very high blood pressure, or a sharp drop in urine output means you should call 911 or go to the ER at once.
The Bottom Line
Scleroderma is a serious autoimmune disease in which outcomes depend heavily on detecting and treating organ involvement before damage becomes irreversible. Routine screening for lung, heart, and kidney complications matters in every patient with systemic sclerosis, and scleroderma renal crisis is a true emergency. Modern organ-targeted therapies – antifibrotics for ILD, pulmonary-hypertension drugs, ACE inhibitors for renal crisis – have transformed the disease’s natural history, even though no cure yet exists. Connecting with a rheumatologist experienced in scleroderma, ideally at or in consultation with a specialized center, gives the best chance of long-term control. Patients who engage actively in monitoring and symptom management consistently do better than those who wait for problems to surface.
This article is general education, not medical advice, and is not a substitute for care from a qualified clinician. Scleroderma requires individualized, specialist-directed treatment, and there is no cure. Do not start, stop, or change any medicine on your own, and do not use any dose you read online – all dosing is prescriber-directed. Scleroderma renal crisis is a medical emergency: for sudden severe high blood pressure, severe headache, a sharp drop in urine output, or severe shortness of breath, call 911 or go to the nearest emergency room.
Sources
- MedlinePlus (U.S. National Library of Medicine) — Scleroderma / systemic sclerosis: types, symptoms, and that the disease has no cure
- Scleroderma Foundation — What Is Scleroderma? and Forms of Scleroderma
- American College of Rheumatology (ACR) — Scleroderma patient information: diagnosis, treatment, and organ monitoring
- NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) — Scleroderma overview and prevalence context